

DPNCheck®

## DPNCheck® Normative Data: Collection, Analysis, and Recommended Normal Limits



## Introduction

A normal limit is a value below (or above) which a diagnostic test result is deemed abnormal. Nerve conduction normal limits depend on measurement variables including instrument specifications, electrode placement, and temperature compensation.<sup>1</sup> Best practices dictate use of normal limits developed from data obtained with identical methods to those used in clinical practice.<sup>1</sup>

A study meeting recommended quality standards<sup>1-3,18</sup> was conducted to develop normal limit recommendations for clinicians using the DPNCheck device. The first objective of this study was to obtain a large database of sural nerve conduction responses, using the DPNCheck device, in a population of normal non-neuropathic subjects. The second objective was to derive normal limits for the sural response amplitude and conduction velocity (CV).

## Methods

This was a prospective study of a broad spectrum population. Potential study subjects were recruited, between August and October 2012, from communities in two US states (Massachusetts and Iowa) through advertising, referrals, testing days at technology and light manufacturing companies, and testing days at senior centers. Recruited subjects completed written informed consent and a clinical questionnaire. The questionnaire included demographics (gender, age, height, and weight), a medical history suggestive of peripheral neuropathy risk (e.g., previously diagnosed neuropathy, diabetes, cancer), and the Diabetic Neuropathy Symptom (DNS) score.<sup>4</sup> The DNS score consists of 4 questions (see Table 1) and is a validated predictor of peripheral neuropathy.

Inclusion criteria were age over 18 and no physical impediment to testing the sural nerve bilaterally. Exclusion criteria were any of the following (i) BMI > 35 kg/m<sup>2</sup>, (ii) medical history positive for peripheral neuropathy, diabetes, renal failure, cancer, hypothyroidism, B12 deficiency, or alcoholism, and (iii) DNS score > 0.

Table 1. Diabetic Neuropathy Symptom (DNS) Questionnaire

1. Are you unsteady when you walk?
2. Do you have a burning, aching pain or tenderness at your legs or feet?
3. Do you have prickling sensations in your legs or feet?
4. Do you have places of numbness on your legs or feet?

Each question answered yes or no.  
Score is the number of yes answers.

All subjects underwent bilateral sural nerve conduction testing. All nerve conduction tests were performed using the DPNCheck device (Software Version 2.0). Two tests were performed on each limb for a total of 4 sural responses per subject. The sural nerve was stimulated, using stainless steel probes, just posterior to the lateral malleolus. The sural response was recorded 92.2 mm proximally at the calf with a pair of electrodes (25 mm length) in a bipolar configuration (20 mm center to center spacing). The nerve was stimulated supramaximally with averaging of 4-7 responses. The amplitude was measured peak to peak. An undetectable sural response was defined as amplitude less than 1.5  $\mu$ V and was displayed as 0  $\mu$ V. The CV was measured to the onset of the initial negative deflection. If the onset could not be reliably determined then CV was not reported. Skin temperature was monitored by an infra-red digital thermometer with CVs normalized to 28°C using a temperature correction factor of 1 m/s per °C. The DPNCheck device displays amplitude and CV as rounded whole numbers (e.g., 6  $\mu$ V, 52 m/s) per recommended reporting precision.<sup>1</sup>

The study data set was created by taking a single sural response (first test on left limb) from each subject in the study population. Amplitude and CV normal limits were defined as the lower 5<sup>th</sup> percentile. The use of the 5<sup>th</sup> percentile is based on the accepted practice of a 5% false-positive rate in statistical testing. This level has been adopted in several published nerve conduction normal



limit studies.<sup>1,6,7</sup> Because the 5<sup>th</sup> percentile represents a specificity of 95%, the positive predictive value of an abnormal test will be high in patients with moderate pre-test probability of peripheral neuropathy. For example, in a typical diabetic population the pre-test probability is at least 50%<sup>8</sup> and therefore the positive predictive value is greater than 90%, even if test sensitivity is relatively low.

The dependence of the normal limits on demographic variables (e.g., subject age, height) was evaluated using quantile regression.<sup>3</sup> Using this method, the normal limit is expressed as a linear function of demographic variables:

$$Normal\ Limit = K + C_1V_1 + C_2V_2 + \dots + C_nV_n$$

where  $K$  is a constant,  $V_i$  is the  $i^{th}$  demographic variable, and  $C_i$  is the coefficient for the  $i^{th}$  demographic variable. Demographic variables that were statistically significant predictors ( $p < 0.05$ ) of the normal limit were retained. The precision of the resulting normal limits was assessed by calculating both point estimates and 95% confidence intervals (95% CI) for representative demographics using the bootstrap method with 100,000 random samples. A precise normal limit has a narrow confidence interval, indicating the appropriateness of the nerve conduction and statistical methods.<sup>9</sup>

## Results

A total of 856 subjects were recruited. Of these, 329 (38.4%) met the exclusion criteria leaving a study population of 527. Study subject characteristics are summarized in Table 2. The mean age was 48.3 years, with 21.8% of the subjects 65 years or older.

The amplitude normal limit was statistically dependent on subject age, decreasing by 0.99 (95% CI, 0.60 – 1.3)  $\mu V$  per decade. Figure 1 shows the relationship between age and amplitude. The green line is the age dependent normal limit.

The CV normal limit was statistically dependent on subject age and height, decreasing 1.3 (95% CI, 1.0 – 1.7) m/s

per decade and 2.0 (95% CI, 1.4 – 2.6) m/s per 10 cm, respectively.

Figure 2 shows the relationship between height and CV. The two green lines show the height dependent normal limits for subjects 45 (upper line) and 65 (lower line) years of age. Table 3 shows estimates of normal limits and confidence intervals for subjects aged 25, 45, and 65 years and height 172 cm.

Table 2. Study subject characteristics.

Characteristic	Mean (Stdev) or %
Gender (% Female)	51.2
Age (years)	48.3 (18.5)
Height (cm)	167 (11.5)
Weight (kg)	73.1 (16.8)
BMI (m/kg <sup>2</sup> )	26.0 (4.09)
Amplitude ( $\mu V$ )	16.9 (8.62)
Conduction Velocity (m/s)*	53.0 (5.17)

\*Conduction velocity available for 523 subjects

Table 3. Point estimates and confidence intervals for ages 25, 45 and 65 years.

Parameter	5th Percentile Normal Limit (95% CI)		
	25 yrs	45 yrs	65 yrs
Amplitude ( $\mu V$ )	9 (8–10)	7 (6–8)	5 (4–6)
CV (m/s)	48 (47–49)	45 (45–46)	43 (42–44)

Two of the 527 (0.38%) study subjects had an undetectable sural response among their 4 tests. On this basis, an undetectable response was estimated to have specificity of over 99.5%. The two subjects had ages 58 and 67 years. Although they did not report any prospective exclusion criteria, one of the subjects had a partial foot amputation.




Figure 1. Relationship between subject age and sural nerve amplitude. Green line indicates recommended age dependent normal limit.




Figure 2. Relationship between subject height and sural nerve CV. Upper and lower green lines indicate recommended height dependent normal limit for subjects 45 and 65 years of age, respectively.

## Discussion

The purpose of this study was to develop a large database of DPNCheck data in subjects without evidence of neuropathy and to use the data set to establish statistically robust normal limits. Sural amplitude was found to depend on subject age, declining about 1  $\mu\text{V}$  for every decade.

This clinically significant amplitude reduction represents a 153 fibers/ $\text{mm}^2$  reduction in sural nerve myelinated fiber density.<sup>10</sup> Sural conduction velocity was dependent on both age and height, decreasing by 1.3 m/s for every decade and 2.0 m/s for every 10 cm of height.

The normal limit confidence intervals for both sural amplitude and CV were narrow, at about 1  $\mu\text{V}$  and 1 m/s respectively. These values support the validity of the nerve conduction and analysis methods used in the present study. These confidence intervals are narrower than prior reports of sural normal limits,<sup>6,7</sup> reflecting the large sample size. Over 20% of the subjects in the present study were at least 65 years of age. The narrow confidence intervals in this age group and the low rate of undetectable responses suggest the recommended normal limits are reliable in elderly subjects.

Despite studies suggesting that nerve conduction normal limits vary with demographic variables,<sup>1</sup> it remains common practice to use fixed thresholds. The disadvantage of this approach is that diagnostic specificity will vary with the patient's age and potentially other demographic characteristics. The specificity may be very high in younger and short patients, but only modest in elderly and the very tall. For example, at a fixed normal limit of 5  $\mu\text{V}$  (i.e., amplitudes 4  $\mu\text{V}$  or less are labeled abnormal), the overall specificity in this study population is 96.6%, which is similar to the target specificity of 95%. However, the specificity varies with age. It is 100% for subjects < 45 years, 98.1% for subjects 45-64 years, and 87.0% for subjects  $\geq$  65 years. By contrast, when using the recommended age dependent normal limits, the specificity is 94.6%, 96.1% and 93.0% for the three age groups.



A number of studies have reported sural normal limits.<sup>6,7,11-17</sup> The sample size in the present study (N=527) is the largest among prospective studies meeting recommended quality standards for collection and analysis of normative data.<sup>1,2,18</sup>

Hirayasu and colleagues<sup>19</sup> carried out a normal limits study with DPNCheck in a cohort of 463 Japanese subjects without clinical evidence of neuropathy. The authors used identical statistical methods to the present study and found similar normal limits, attributing the small differences to population characteristics. Although comparisons of specific normal limit values must account for differences in methodology, relevant conclusions can be drawn from the general findings in studies that used traditional nerve conduction equipment.

In a widely referenced study, Stetson and colleagues<sup>13</sup> reported sural normal limits in 105 subjects using ordinary linear regression and Gaussian transformation of nerve conduction parameters. They found that sural amplitude was related to gender, age and height and conduction velocity to height. The authors suggested calculation of sural normal limits as 2 standard deviations below the demographic adjusted mean.

Although this parametric approach is common,<sup>1,11,12,17</sup> it makes the generally incorrect assumption that amplitude and conduction velocity variance are independent of demographics.<sup>3,14</sup>

Benatar and colleagues<sup>7</sup> reported sural normal limits, including the 5<sup>th</sup> percentile, in 190 subjects using quantile regression. Similar to the present study, they found that sural amplitude was related to age. In contrast to the present and other studies,<sup>11,13,14</sup> they did not find a statistically and clinically significant relationship between conduction velocity and age or height.

Esper and colleagues<sup>6</sup> evaluated the relationship between the sural amplitude normal limit at the 5<sup>th</sup> percentile and age in 92 subjects using conventional percentiles<sup>1</sup> and the bootstrap method. They reported a dramatic drop in the normal limit with age, decreasing from 14.0 (95%

CI, 10.4–19.0)  $\mu$ V in subjects < 40 years to 3.2  $\mu$ V (95% CI, 2.1–5.6) in subjects  $\geq$  60 years. Although the broad confidence intervals obscured the exact normal limits, the conclusion of a strong dependence of the amplitude normal limit on age was robust.

## Recommendations

The values in Table 4 may be entered into the DPNCheck Reporter™ software to implement the normal limits described above.

There are two options for CV. The first option includes adjustments for age and height. The second option assumes a fixed height of 182.9 cm (6 feet) for those situations where height is not readily available (e.g., when automatically processing data based on electronic health record orders). This fixed height is greater than 87% of 65 year old men and 99% of 65 year old women in the U.S. and therefore insures high detection specificity (source U.S. Census Bureau website).

These recommendations are provided for informational purposes only and do not constitute medical advice. A decision to utilize this information must be made by an appropriately trained medical professional.

Table 4. Recommended Normal Limits.

Parameter	Constant	Age Coefficient	Height Coefficient
Amplitude	11.2	-0.099	0
CV	85.5	-0.13	-0.20
CV*	49.3	-0.13	0

\*CV normal limit with constant height of 182.9 cm (6 feet).



## References

1. Dorfman LJ, Robinson LR. AAEM minimonograph #47: normative data in electrodiagnostic medicine. *Muscle Nerve*. Jan 1997;20(1):4-14.
2. Solberg HE. The theory of reference values Part 5. Statistical treatment of collected reference values. Determination of reference limits. *J Clin Chem Clin Biochem*. Nov 1983;21(11):749-760.
3. Peng L, Wu J, Benatar M. Developing reference data for nerve conduction studies: an application of quantile regression. *Muscle Nerve*. Nov 2009;40(5):763-771.
4. Meijer JW, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. *Diabet Med*. Nov 2002;19(11):962-965.
5. Trojaborg WT, Moon A, Andersen BB, Trojaborg NS. Sural nerve conduction parameters in normal subjects related to age, gender, temperature, and height: a reappraisal. *Muscle Nerve*. Jun 1992;15(6):666-671.
6. Esper GJ, Nardin RA, Benatar M, Sax TW, Acosta JA, Raynor EM. Sural and radial sensory responses in healthy adults: diagnostic implications for polyneuropathy. *Muscle Nerve*. May 2005;31(5):628-632.
7. Benatar M, Wu J, Peng L. Reference data for commonly used sensory and motor nerve conduction studies. *Muscle Nerve*. Nov 2009;40(5):772-794.
8. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. *Neurology*. Apr 1993;43(4):817-824.
9. Reed AH, Cannon DC, Pileggi VJ, Winkelman JW. Use of confidence intervals to assess precision of normal range estimates. *Clin Biochem*. Mar 1973;6(1):29-33.
10. Russell JW, Karnes JL, Dyck PJ. Sural nerve myelinated fiber density differences associated with meaningful changes in clinical and electrophysiologic measurements. *J Neurol Sci*. Feb 1996;135(2):114-117.
11. Rivner MH, Swift TR, Crout BO, Rhodes KP. Toward more rational nerve conduction interpretations: the effect of height. *Muscle Nerve*. Mar 1990;13(3):232-239.
12. Rivner MH, Swift TR, Malik K. Influence of age and height on nerve conduction. *Muscle Nerve*. Sep 2001;24(9):1134-1141.
13. Stetson DS, Albers JW, Silverstein BA, Wolfe RA. Effects of age, sex, and anthropometric factors on nerve conduction measures. *Muscle Nerve*. Oct 1992;15(10):1095-1104.
14. Kong X, Schoenfeld DA, Lesser EA, Gozani SN. Implementation and evaluation of a statistical framework for nerve conduction study reference range calculation. *Comput Methods Programs Biomed*. Jan 2010;97(1):1-10.
15. Burke D, Skuse NF, Lethlean AK. Sensory conduction of the sural nerve in polyneuropathy. *J Neurol Neurosurg Psychiatry*. Jun 1974;37(6):647-652.
16. Kokotis P, Mandellos D, Papagianni A, Karandreas N. Nomogram for determining lower limit of the sural response. *Clin Neurophysiol*. Apr 2010;121(4):561-563.
17. Luigetti M, Quaranta D, Modoni A, Mereu ML, Lo Monaco M. Nerve conduction studies of the sural nerve: normative data from a single-center experience. *Clin Neurophysiol*. Sep 2012;123(9):1891-1892.
18. Dillingham T, Chen S, Andary M, Buschbacher R, Del Toro D, Smith B, Zimmermann K, So Y. Establishing high-quality reference values for nerve conduction studies: A report from the normative data task force of the American Association Of Neuromuscular & Electrodiagnostic Medicine. *Muscle Nerve*. Sep 2016;54(3):366-70.
19. Hirayasu K, Sasaki H, Kishimoto S, Kurisu S, Noda K, Ogawa K, Tanaka H, Sakakibara Y, Matsuno S, Furuta H, Arita M, Naka K, Nanjo K. Difference in normal limit values of nerve conduction parameters between Westerners and Japanese people might need to be considered when diagnosing diabetic polyneuropathy using a Point-of-Care Sural Nerve Conduction Device (NC-stat®/DPN-Check™). *J Diabetes Investig*. Sep 2018;9(5):1173-1181.

**DPNCheck®**

Alera/TES  
159 W Mason Ave  
Buckley WA 98321  
844.DPN.CHECK (844.376.2432)  
www.dpncheck.com  
customerservice@dpncheck.com  
global@dpncheck.com(Outside USA)